Abstract. We hypothesized that adrenergic mechanisms support the postabsorptive plasma glucose concentration, and prevent hypoglycemia when glucagon secretion is deficient. Accordingly, we assessed the impact of glucagon deficiency, produced by infusion of somatostatin with insulin, without and with pharmacologic \(\alpha\)- and \(\beta\)-adrenergic blockade on the postabsorptive plasma glucose concentration and glucose kinetics in normal human subjects. During somatostatin with insulin alone mean glucose production fell from 1.5±0.05 to 0.7±0.2 mg/kg per min and mean plasma glucose declined from 93±3 to 67±4 mg/dl over 1 h; glucose production then increased to base-line rates and plasma glucose plateaued at 64–67 mg/dl over 2 h. This plateau was associated with, and is best attributed to, an eightfold increase in mean plasma epinephrine. It did not occur when adrenergic blockade was added; glucose production remained low and mean plasma glucose declined progressively to a hypoglycemic level of 45±4 mg/dl, significantly (\(P < 0.001\)) lower than the final value during somatostatin with insulin alone. These data provide further support for the concept that maintenance of the postabsorptive plasma glucose concentration is a function of insulin and glucagon, not of insulin alone, and that adrenergic mechanisms do not normally play a critical role. They indicate, however, that an endogenous adrenergic agonist, likely adrenomedullary epinephrine, compensates for deficient glucagon secretion and prevents hypoglycemia in the postabsorptive state in humans. Thus, postabsorptive hypoglycemia occurs when both glucagon and epinephrine are deficient, but not when either glucagon or epinephrine alone is deficient, and insulin is present.

Introduction

The physiologic mechanisms of hypoglycemic glucose counterregulation—those that promote recovery from hypoglycemia—have been defined (1–7). Glucose recovery is not due solely to dissipation of insulin. Glucagon plays a primary counterregulatory role; epinephrine compensates largely for deficient glucagon secretion. Glucose recovery fails to occur only in the absence of both glucagon and epinephrine. Although other hormonal factors, neural mechanisms, and hepatic autoregulation may be involved, they need not be invoked and are not sufficiently potent to promote recovery from hypoglycemia when the key counterregulatory hormones, glucagon and epinephrine, are deficient.

More recently it has been shown that the same principles apply to nonhypoglycemic glucose counterregulation—the physiologic mechanisms that blunt physiologic decrements in plasma glucose, prevent hypoglycemia, and restore or maintain euglycemia—in that they apply to regulation of the transition from exogenous glucose delivery to endogenous glucose production late after glucose ingestion (8, 9).

There is considerable evidence, reviewed by Gerich (10, 11), that glucagon supports postabsorptive glucose production and, therefore, the postabsorptive plasma glucose concentration. Somatostatin suppresses glucagon (and insulin) secretion and causes an initial decrease in glucose production and plasma glucose. This effect of somatostatin is prevented by glucagon replacement. Further, the small decrement in plasma glucose that follows induction of glycosuria in dogs is converted to a substantial decrement when glucagon secretion is suppressed by somatostatin (12). Despite decrements in plasma glucose, however, glucagon deficiency per se does not produce absolute hypoglycemia (10–13). On the other hand, adrenergic mechanisms do not support postabsorptive glucose production (2) in normal...
humans, and postabsorptive plasma glucose concentrations are not discernibly reduced in epinephrine-deficient (adrenalectomized) persons (3, 9).

Thus, maintenance of the postabsorptive plasma glucose concentration is a coordinated function of insulin and glucagon, adrenergic mechanisms do not normally play a critical role, and epinephrine compensates for deficient glucagon secretion in hypoglycemic glucose counterregulation and in at least one example of nonhypoglycemic glucose counterregulation. Therefore, we hypothesized that adrenergic mechanisms support the postabsorptive plasma glucose concentration and prevent hypoglycemia when glucagon secretion is deficient. In an initial study (13) we found that combined α- and β-adrenergic blockade blunts the late increase in glucose production and plasma glucose that follows their initial decrease during combined insulin and glucagon deficiency produced by infusion of somatostatin. Adrenergic blockade did not, however, result in a progressive decline in plasma glucose. We reasoned that this was because insulin secretion, as well as that of glucagon, was suppressed. Therefore, we assessed the impact of glucagon deficiency produced by infusion of somatostatin with insulin, without and with pharmacologic adrenergic blockade on the postabsorptive plasma glucose concentration and glucose kinetics in normal human subjects.

Methods

10 normal human subjects (six women and four men), whose ages ranged from 18 to 33 yr and who were within 15% of ideal body weight, gave their informed, written consent to participate in this study, which was approved by the Washington University Human Studies Committee. We performed the study at the Washington University General Clinical Research Center.

After an overnight fast, subjects assumed the supine position, which was maintained throughout. Intravenous catheters were inserted for drug/radiochemical infusions in one arm and for blood sampling in the opposite arm. A primed (20.0 μCi), continuous (0.2 μCi/min) infusion of [3-14C]glucose (11.5 Ci/mmol, New England Nuclear, Boston, MA) was begun at 1–10 min and continued through 180 min. Somatostatin (Beckman Instruments, Inc., Bioproducts Div., Stanford, CA) was infused in a dose of 250 μg/h, and regular porcine insulin (Iletin II; Eli Lilly & Co., Indianapolis, IN) was infused in a dose of 200 μU/kg per min, from 0 through 180 min. On a separate occasion the same protocol was followed with addition of infusions of propranolol (Inderal; Ayerst Laboratories, New York, NY, in a dose of 0.08 mg/min after 5.0 mg over 2 min, and phentolamine (Regitine; Ciba-Geigy Corp., Pharmaceuticals Div., Summit, NJ) in a dose of 0.5 mg/min after 5.0 mg over 2 min, from 30 through 180 min. The sequence of studies was varied randomly. Blood samples were drawn, and the blood pressure and heart rate recorded, at 10-min intervals from 60 through 180 min.

Plasma glucose was determined with a glucose oxidase method and plasma glucose appearance and disappearance rates were calculated from the specific activities of tritiated glucose (14, 15). Plasma insulin (16), C-peptide (17), glucagon (18), growth hormone (19), and cortisol (20) were measured by radioimmunoassay. Antisera to cortisone was used to measure glucagon and an antisera purchased from Calbiochem-Behring Corp. (La Jolla, CA) to measure C-peptide. Plasma epinephrine and norepinephrine were measured with a single isotope derivative assay (21) employing 50-μl samples. Detection limits were 3.1 μU/ml for insulin, 1.0 ng/ml for C-peptide, 45 pg/ml for glucagon, 0.4 ng/ml for growth hormone, 3.0 μg/dl for cortisol, and 10 pg/ml for both epinephrine and norepinephrine. Blood alanine (22), lactate (23), glycerol (24), and β-hydroxybutyrate (24) were measured with microfluorometric enzymatic techniques.

The data (mean±SE) were analyzed with a t test for paired data.

Results

During infusion of somatostatin with insulin the mean plasma glucose concentration declined from 93±3 to 67±4 mg/dl at 60 min, but then plateaued at 64–67 mg/dl. The 180-min value was 64±4 mg/dl, not significantly different from the 60-min value. The initial decline (91±3–67±4 mg/dl at 60 min) was similar during somatostatin with insulin coupled with propranolol plus phentolamine. However, plasma glucose did not plateau, but rather declined progressively to a 180-min value of 45±4 mg/dl, significantly (P < 0.001) lower than the 180-min value of 64±4 mg/dl during somatostatin with insulin alone. The points comprising the glucose curves, illustrated in Fig. 1, were significantly different from 100 through 180 min.

There were no consistent symptoms during somatostatin with insulin. Symptoms such as hunger and diaphoresis occurred in all subjects during somatostatin with insulin and propranolol plus phentolamine; impaired mentation, a mandatory stop point, occurred in two subjects. For data analysis the last value for each parameter from these two subjects was used in the calculation of later means.

Somatostatin with insulin resulted in an initial fall in glucose production (plasma glucose appearance rate, Rg) from 1.5±0.05 mg/kg per min to a nadir of 0.7±0.2 mg/kg per min at 50 min (Fig. 1). Glucose production then rose to approximate basal rates from 70 through 180 min. There were no changes in glucose utilization (plasma glucose disappearance rate, Ru). The initial fall in glucose production (from 1.5±0.1 mg/kg per min to a nadir of 0.6±0.2 mg/kg per min at 40 min) was similar during somatostatin with insulin coupled with propranolol plus phentolamine. However, the subsequent rise in glucose production was markedly attenuated; mean rates remained below base line and were significantly (P < 0.05) lower than during somatostatin with insulin alone by 80 min (Fig. 1). Again, there were no changes in glucose utilization. Thus, the progressive decline in the plasma glucose concentration was the result of reduced glucose production.

Plasma concentrations of potentially important glucoregulatory factors are also shown in Fig. 1. Plasma C-peptide, insulin, and glucagon concentrations were comparable under both study conditions. Plasma C-peptide was suppressed by 65–70% and plasma growth hormone was suppressed by 70–80%, indicating the efficacy of the infused somatostatin. These represent minimum estimates of the degree of suppression since C-peptide and growth hormone levels were suppressed to levels below the sensitivity of the assays in most of the subjects. The measured
decrements in plasma glucagon were small. However, since the antiserum used crossreacts with species in addition to 3,500-dalton glucagon (25), and somatostatin suppresses 3,500-dalton glucagon preferentially (26–28), biologically active glucagon was likely suppressed substantially. The resultant of somatostatin-induced suppression of insulin secretion, as evidenced by the C-peptide data, and insulin replacement, was peripheral venous insulin concentrations ~20–60% above base-line values. Since the normal hepatic portal-to-peripheral venous insulin concentration ratio is ~2.5:1.0 (29–32), this mild peripheral hyperinsulinemia must have been associated with portal hypoinsulinemia.

Plasma growth hormone concentrations were not significantly different under the two study conditions. However, increments in plasma growth hormone occurred in 3 of 10 subjects during somatostatin with insulin coupled with propranolol and phenotolamine, likely a response to low plasma glucose concentrations (33) and indicating escape of growth hormone secretion from the suppressive effect of somatostatin in these three individuals. Such escape has been described previously for glucagon (34) but not, to our knowledge, for growth hormone. There was no evidence of similar escape of insulin secretion (which would not be expected since plasma glucose levels were low) from the C-peptide data. Further, there was no evidence of escape of glucagon secretion that, if it occurred, would have tended to raise the plasma glucose concentration and would, therefore, not explain the glucose findings.

During somatostatin with insulin coupled with propranolol plus phenotolamine plasma cortisol rose to a final value of 25±4 μg/dl, significantly (P < 0.01) higher than the corresponding value to 16±3 μg/dl during somatostatin with insulin alone. This was undoubtedly the result of substantially lower plasma glucose concentrations during the former study (33).

Figure 1. Mean (±SE) plasma glucose concentrations, plasma glucose appearance rates and plasma disappearance rates, and plasma concentrations of C-peptide, insulin, glucagon, growth hormone, cortisol, epinephrine, and norepinephrine during infusions of somatostatin (SRIF) with insulin alone, filled circles, and during infusions of somatostatin (SRIF) with insulin plus propranolol (PRP) and phenolamine (PTL), open circles, in 10 normal human subjects.

Plasma epinephrine concentrations rose more than eightfold, from 18±4 to 153±33 pg/ml (P < 0.01) at 180 min, during somatostatin with insulin. Plasma epinephrine levels reached 150±28 pg/ml (P < 0.001) at 90 min and remained elevated thereafter. Similar increments in epinephrine in response to similar decrements in plasma glucose have been reported previously from our laboratory (33). Plasma norepinephrine concentrations also increased, from 156±11 to 271±29 pg/ml (P < 0.01), during somatostatin with insulin, although the increase was more gradual than that of epinephrine. The first value significantly higher than base line was 231±22 pg/ml (P < 0.01) at 130 min. As shown in Fig. 1, propranolol plus phenolamine did not alter plasma epinephrine concentrations significantly, but increased plasma norepinephrine levels from 171±20 to 418±61 pg/ml (P < 0.01) before initiation of somatostatin with insulin. Phenolamine is known to increase plasma norepinephrine (35), which is likely the result of increased norepinephrine release due to presynaptic α2-adrenergic receptor blockade, perhaps coupled with reflex sympathetic activation triggered by the small decrease in blood pressure produced by phenolamine (see below). Further, propranolol decreases the clearance of catecholamines from the circulation (36). Propranolol plus phenolamine markedly enhanced the plasma catecholamine responses to decrements in plasma glucose during somatostatin with insulin. Plasma epinephrine rose to a 180-min value of 2,110±510 pg/ml, significantly (P < 0.01) higher than the corresponding value of 153±33 pg/ml during soma-

407  Postabsorptive Glucoregulation
somatostatin with insulin alone. Plasma norepinephrine rose to a 180-min value of 1,060±225 pg/ml, significantly (P < 0.01) higher than the corresponding value of 271±29 pg/ml during somatostatin with insulin alone.

Blood concentrations of metabolic intermediates are shown in Fig. 2. During somatostatin with insulin alone blood lactate rose from 770±84 to a peak of 1,095±136 μmol/liter (P < 0.02) at 130 min; this rise did not occur during somatostatin with insulin coupled with propranolol plus phentolamine (683±60–817±53 μmol/liter). Blood alanine rose from 303±23 to a peak of 347±29 μmol/liter (P < 0.05) at 150 min during somatostatin with insulin alone and similarly, from 285±23 to 338±23 μmol/liter (P < 0.02) during somatostatin with insulin coupled with propranolol plus phentolamine. Blood glycerol declined from 83±6 to a nadir of 55±7 μmol/liter (P < 0.02) at 40 min and then rose to 89±21 μmol/liter at 160 min during somatostatin with insulin alone. In contrast, during somatostatin with insulin coupled with propranolol plus phentolamine, blood glycerol declined progressively from 84±9 to 64±9 μmol/liter at 40 min, to 39±5 μmol/liter at 160 min, (P < 0.05 vs. the control value of 89±21 μmol/liter). Blood β-hydroxybutyrate levels declined from 128±21 to 75±5 μmol/liter (P < 0.02) at 60 min and remained at about that level thereafter during somatostatin with insulin alone; similar changes (114±13 to 66±4 μmol/liter) occurred during somatostatin with insulin coupled with propranolol plus phentolamine.

As shown in Table 1, there were no significant changes in heart rate or blood pressure during somatostatin with insulin alone although heart rate tended to rise. During somatostatin with insulin coupled with propranolol plus phentolamine, mean heart rates, systolic blood pressures, and diastolic blood pressures were significantly lower than those during somatostatin with insulin alone.

Discussion

These data document that adrenergic mechanisms, likely mediated by adrenomedullary epinephrine, support the postabsorptive plasma glucose concentration, and prevent hypoglycemia, when glucagon secretion is suppressed, insulin is present, and plasma glucose levels are lowered in normal human subjects.

There is considerable evidence that glucagon normally supports postabsorptive glucose production and functions in concert with insulin to maintain the postabsorptive plasma glucose concentration (10, 11, 13). The present studies were not designed to reassess this concept, but the findings are consistent with it. The dose of insulin (200 μU/kg per min) that we infused with somatostatin was a compromise. Ideally, we would have wished to produce isolated glucagon deficiency by infusing somatostatin with insulin in a dose sufficient to maintain portal insulin concentrations at base-line levels. That is, of course, impractical with peripheral venous infusions. Thus, we selected an insulin dose that, when infused with somatostatin, produced mild peripheral venous hyperinsulinemia and portal venous insulin levels that can be estimated (from the measured peripheral insulin levels at base line and during infusions and from the degree of C-peptide suppression) to be approximately two-thirds of base-line levels. Nonetheless, the initial decrease in glucose production and plasma glucose, with no increase in glucose utilization, provide biologic evidence of isolated glucagon deficiency. Thus, we produced greater initial decrements in plasma glucose than did Saccà et al. (37) despite the fact that they infused larger doses of insulin and did not suppress endogenous insulin (or glucagon) secretion and thus produced peripheral venous insulin levels ~25% higher (the difference in portal venous insulin levels may well have been greater) than those in the present study. Nonetheless, the latter data clearly underscore the fact that moderate hyperinsulinemia can result in decrements in plasma glucose despite normal glucagon secretion. Since such glucose decrements do not result in hypoglycemia (37), effective glucose counterregulatory systems must be operative. The present data indicate that these include epinephrine as well as glucagon and that other hormonal, neural, or autoregulatory mechanisms need not be invoked.

After an initial decrease, glucose production rose to approximate basal rates and mean plasma glucose plateaued at 64–67 mg/dl over 2 h despite ongoing suppression of glucagon secretion. Thus, a factor in addition to glucagon must support the postabsorptive plasma glucose concentration, at least when glucagon secretion is deficient and plasma glucose levels are lowered. The finding of temporally related increments in plasma epinephrine suggests that this factor is an adrenomedullary discharge. This suggestion is supported by the results of the study with pharmacologic adrenergic blockade.

The plateau of plasma glucose that occurred during glucagon deficiency produced by somatostatin with insulin did not occur when glucagon deficiency was produced during combined α- and β-adrenergic blockade with propranolol and phenolamine.
Thus, norepinephrine, neural the in normal adrenalectomy crease in system. Insulin-induced rather than in sympathetic pensates but epinephrine, glucose hypoglycemic occurred and to a contrast, the somatostatin with norepinephrine for deficient. is and glucose both studies. glucose production. mean level, hypoglycemic started. insulin and epinephrine, PRP, propranolol; PTL, phentolamine; NS, not significant. * Propranolol and phentolamine started. † Somatostatin with insulin started.

Rather, mean plasma glucose declined progressively to a hypoglycemic level, 45 mg/dl. This decline was the result of reduced glucose production. Insulin and glucagon levels were comparable during both studies. Thus, adrenergic mechanisms support postabsorptive glucose production and the plasma glucose concentration, and prevent hypoglycemia, when glucagon secretion is deficient.

Although these adrenergic mechanisms could be activated by norepinephrine released from sympathetic nerves, it is far more likely that they are activated by adrenomedullary epi-nephrine for three reasons. First, the plasma glucose plateau during somatostatin with insulin alone was temporally associated with a more than eightfold increase in mean plasma epinephrine to a level known to have hyperglycemic effects in man (38). In contrast, the increment in plasma norepinephrine was small and occurred considerably later. Second, in both hypoglycemic glucose counterregulation (1–7) and in another model of non-hypoglycemic glucose counterregulation (9), adrenomedullary epinephrine, but not sympathetic neural norepinephrine, compensates for deficient glucagon secretion. Third, measurements of sympathetic activity by means of tissue norepinephrine turn-over in rats (39, 40) have shown that hypoglycemia suppresses, rather than stimulates, the activity of the sympathetic nervous system. Insulin-induced hypoglycemia fails to produce an increase in plasma norepinephrine in persons who have undergone bilateral adrenalectomy (3), indicating that the small increment seen in normal subjects is the result of norepinephrine release from the adrenal medullae rather than from sympathetic nerves. Thus, it is adrenomedullary epinephrine, rather than sympathetic neural norepinephrine, that supports the postabsorptive plasma glucose concentration when glucagon is deficient. The kinetic data indicate that this is largely the result of an epinephrine-induced increase in glucose production. However, epinephrine is known to both stimulate glucose production and limit glucose utilization (41). The present data do not exclude an additional effect of epinephrine on glucose utilization during glucagon deficiency.

Increments in blood lactate and blood glycerol, indices of glycolysis and lipolysis, respectively, occurred during glucagon deficiency. These changes were prevented by combined adrenergic blockade and provide further evidence of biologically active epinephrine release in response to the plasma glucose decrements produced by glucagon deficiency.

In summary, maintenance of the postabsorptive plasma glucose concentration is a coordinated function of insulin and glucagon, not of insulin alone, in man. Adrenergic mechanisms do not normally play a critical role. However, epinephrine compensates for deficient glucagon secretion and prevents hypoglycemia. Thus, postabsorptive hypoglycemia occurs when both glucagon secretion and epinephrine are deficient and insulin is present. Although other hormonal, neural, or autoregulatory counterregulatory factors may be involved in maintenance of the postabsorptive plasma glucose concentration, they need not be invoked and they are not sufficiently potent to prevent postabsorptive hypoglycemia when the key glucose counterregulatory hormones, glucagon and epinephrine, are deficient.

This synthesis should not be interpreted to suggest that the counterregulatory function of epinephrine is limited to glucagon-deficient states. It is quite conceivable that epinephrine prevents hypoglycemia when sustained hyperinsulinemia or other}
lowering factors are sufficient to overcome the counterregulatory actions of glucagon and result in a decrement in plasma glucose. We would suggest, as an operational model, that small fluctuations in plasma glucose are regularly modulated by insulin and glucagon, whereas more substantial decrements in plasma glucose, regardless of their initiating mechanism, elicit adrenergic or somatostatic responses and that epinephrine in concert with glucagon blunts the glucose decrements and prevents hypoglycemia.

These data indicate that maintenance of a level of plasma glucose adequate for normal cerebral function, and thus essential for survival, is accomplished by redundant defenses against hypoglycemia. Postabsorptive hypoglycemia does not occur during deficiency of either glucagon (10, 11, present data) or epinephrine (2, 3, 9, 13) alone, nor during combined deficiency of glucagon and epinephrine when insulin secretion is also suppressed (13). Hypoglycemia due to glucoregulatory abnormalities occurs only when both glucagon and epinephrine are deficient and insulin is present or insulin levels are high enough to overwhelm counterregulatory mechanisms. The presence of redundant defenses against the development of postabsorptive hypoglycemia accounts for the ability of many insulin-treated patients with insulin-dependent diabetes mellitus to maintain their plasma glucose at levels sufficient for normal cerebral function despite hyperinsulinemia and deficient glucagon responses, as well as the susceptibility to hypoglycemia of those patients in whom epinephrine secretion is also deficient (7).

Thus, the principles of hypoglycemic glucose counterregulation (1–7) and those of nonhypoglycemic glucose counterregulation in both the postprandial (8, 9) and the postabsorptive states are fundamentally the same. Counterregulation is not due solely to dissipation of insulin. Glucagon plays a primary counterregulatory role, whereas epinephrine compensates largely for deficient glucagon secretion; epinephrine may also compensate for insufficient glucagon action. Counterregulation fails, and hypoglycemia occurs, when both glucagon and epinephrine are deficient and insulin is present.

Acknowledgments

The authors acknowledge the technical assistance of Ms. Eva Sorenson, Mr. Krishan Jethi, Ms. Denise Nachowiak, Ms. Joy Brothers, and Ms. Bakula Trivedi, the secretarial assistance of Ms. Theresa Lautner, and the assistance of the nursing staff of the Washington University General Clinical Research Center.

This work was supported by U. S. Public Health Service grants AM27085, AM20579, and RR00036.

References


